Ameriprise’s Moderna MRNA Stock Holding History

Ameriprise’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-383,900	Closed	-$9.92M	–	4169
2025 Q3	$9.92M	Buy	+383,900	New	+$10.7M	﹤0.01%	1917

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise's MRNA Position: Q1 2026 in Review

Ameriprise reduced its Moderna (MRNA) stake by 34% in Q1 2026, selling an estimated $3.48M and leaving 143,449 shares worth $7.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2176.

Ameriprise first reported a position in MRNA in Q2 2019 and has held it in 28 quarters since. The position peaked at $93.2M in Q3 2021. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Ameriprise held 143,449 shares of Moderna worth $7.29M as of Q1 2026.
Ameriprise sold 74,611 Moderna shares in Q1 2026, an estimated $3.48M.
Moderna made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2176 holding.
Ameriprise first reported a position in Moderna in Q2 2019 and has held it in 28 quarters since.
Ameriprise's Moderna position peaked at $93.2M in Q3 2021.
723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.